Item 5.02 Departure of Directors or Certain Officers; Election of Directors;
Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.

On March 8, 2013, Dyax Corp. announced that Ivana Magovcevic-Liebisch, Ph.D., J.D., Dyax's Executive Vice President and Chief Operating Officer, is leaving to pursue a senior management opportunity at a multinational pharmaceutical company, effective on March 29, 2013. Dr. Magovcevic-Liebisch will continue to serve the Company as a consultant following her departure.

Item 7.01 Regulation FD Disclosure.

A copy of the press release announcing Dr. Magovcevic-Liebisch's departure is furnished as Exhibit 99.1 to this report.

Item 8.01 Other Events.

On March 6, 2013, Dr. Magovcevic-Liebisch sold 215,359 shares of Dyax common stock. This sale was made independently by an investment professional in an automatic transaction triggered by the occurrence of price limits previously established pursuant to a Rule 10b5-1 plan entered into by Dr. Magovcevic-Liebisch in July 2012.

Item 9.01. Financial Statements and Exhibits.

(d) Exhibits.

99.1 Press release of Dyax Corp. dated March 8, 2013 reporting a management change.

---